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Abstract
Aims/hypothesis Our aim was to investigate amputation-free survival in people at high risk for foot ulceration in diabetes (‘high-
risk foot’), and to compare different subcategories of high-risk foot.
Methods Overall, 17,353 people with diabetes and high-risk foot from January 2008 to December 2011 were identified from the
Scotland-wide diabetes register (Scottish Care Information-Diabetes: N = 247,278). Participants were followed-up for up to
2 years from baseline and were categorised into three groups: (1) those with no previous ulcer, (2) those with an active ulcer
or (3) those with a healed previous ulcer. Participants with prior minor or major amputation were excluded. Accelerated failure
time models were used to compare amputation-free survival up to 2 years between the three exposure groups.
Results The 2 year amputation-free survival rate in all people with diabetes with high-risk foot was 84.5%. In this study group,
270 people (10.0%) had an amputation and 2424 (90.0%) died during the 2 year follow-up period. People who had active and
healed previous ulcers at baseline had significantly lower 2 year amputation-free survival compared with those who had no
previous ulcer (both p < 0.0001). The percentage of people who died within 2 years for those with healed ulcer, active ulcer or no
baseline ulcer was 22.8%, 16% and 12.1%, respectively.
Conclusions/interpretation In people judged to be at high risk of foot ulceration, the risk of death was up to nine times the risk of
amputation. Death rates were higher for people with diabetes who had healed ulcers than for those with active ulcers. However,
people with active ulcers had the highest risk of amputation.
Keywords Amputation . Diabetes . Foot . Mortality . Ulcer
Abbreviations
AFT Accelerated failure time
AIC Akaike’s information criterion
GLP-1 Glucagon-like peptide-1
NHS National Health Service
SCI Scottish Care Information
Introduction
Diabetic foot ulcers and amputations are devastating and
much feared complications of diabetes. Between 15% and
34% of people with diabetes develop a foot ulcer during their
lifetime, with more than half acquiring infections [1] that may
result in lower extremity amputations causing disability, ex-
tensive periods of hospitalisation, and premature mortality [2,
3]. The incidence of major amputation ranges from 0·2 to 2·0
per 1000 people in those with diabetes [4, 5]. Major or minor
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amputation also increases the risk of additional subsequent
amputations [6]. Foot ulcers are the costliest microvascular
complication of diabetes [7].
Amputations in people with diabetes have a significant
impact on ambulation, body care, movement and mobility,
resulting in an inability to perform daily tasks and often a
loss of employment [6] impacting on the wider family.
Clinical epidemiology studies suggest that foot ulcers pre-
cede around 85% of non-traumatic lower extremity amputa-
tions in individuals with diabetes [8] and hence ulcer
prevention is important. Previous studies have reported that
apart from severity of ulcer, age [9], low socioeconomic
status, smoking [10, 11], sex [12], renal impairment [13],
ischaemic heart disease, diabetic neuropathy [14], glucose
levels [15] and peripheral arterial disease [16] are some of
the important factors associated with the risk of amputation.
Identifying a person’s risk of foot ulceration helps in
directing scarce resources to those most at need.
Assessment of individual risk factors can be used to
determine an overall risk score for a person with diabetes;
several systems have been developed and are used in routine
clinical practice [17–21]. Most studies have identified a
history of a previous ulcer as the strongest predictor of
future ulcers [17–20, 22], although a global risk score is a
more sensitive way of predicting foot ulceration than using
any individual risk score [23].
Clinical tools are used to predict which individuals with
active ulcers are at greatest risk of amputation, including the
Wagner, University of Texas, SINBAD and other scores [24].
For people with diabetes who have an active ulcer, the final
healing rates are 65–75% for those attending a hospital clinic,
while around 15–20% of all people with an ulcer undergo
amputation [18, 25–28], depending on duration of follow-
up. Although outcomes have been reported for all people with
diabetes, ulcers and even those with individual risk factors,
there are no reported outcomes for people identified as having
‘high-risk foot’. Additionally, it is recognised that people with
diabetes who have active foot ulcers are as likely to die as to
undergo amputation [18, 25, 26], making amputation-free sur-
vival a more useful clinical outcome than amputation alone
[26]. The aim of this study was to investigate the outcome of
all people with diabetes who had ‘high-risk foot’, using
amputation-free survival rate as the primary outcome. The
factors associated with the risk of amputation in this group
of individuals were also investigated in a secondary analysis.
Methods
Data sources The Scottish Care Information-Diabetes (SCI-
Diabetes) is a national population-based database which was
established in 2000. This database is populated by daily
downloads from primary and secondary care databases and
contains demographic and clinical information covering over
99% of people with a diagnosis of diabetes in Scotland. At the
time of the study there were 247,278 people with diabetes
registered. The SCI-Diabetes database was linked anony-
mously to the national hospital admissions data (the Scottish
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Morbidity Record SMR01) and mortality data, which were
provided by the Information Services Division (ISD) of
National Health Service (NHS) and National Records of
Scotland. Approval for generation and analysis of the linked
dataset was obtained from the Caldicott guardians of all
Health Boards in Scotland, the Privacy Advisory Committee
of the Information Services Division of NHS National
Services Scotland (ISD) and the national Multi-centre
Research Ethics Committee.
Study population From the SCI-Diabetes database (>95%
complete for foot recordings), people with diabetes who had
been scored as ‘high risk’ for foot ulceration based on SIGN
Guideline 116 criteria [17] between January 2008 and
December 2011 were included. Study entry was the first re-
cord of ‘high risk’. In Scotland, individuals are classified as
‘high risk’ if they meet the following criteria: (1) they have
had previous ulceration or amputation; (2) they have both
absent pulses and inability to feel a 10 g monofilament or
(3) they have one of the conditions in (1) or (2) together with
callus or deformity. Greater detail is published elsewhere [17,
18]. Hereafter in this paper, such individuals are described as
having ‘high-risk foot’. To limit confounding between the
exposure groups, only incident amputations (either minor or
major) were included. Thus, people with diabetes who had
any (minor or major) amputation prior to the ‘high risk’ score
were excluded from the study (n = 6654 [1.6%]). People with
diabetes who had a high-risk foot on annual screening were
then categorised into one of three exposure groups according
to baseline data: (1) people with diabetes with no history of a
foot ulcer; (2) those with healed ulcers and (3) those with
active ulcers. The ‘no ulcer’ group had no history of any
previous foot ulcer but had sufficient risk factors to classify
them as ‘high risk’ [17]. The ‘healed ulcer’ group had a pre-
vious foot ulcer that was completely healed at baseline, while
the ‘active ulcer’ group had a foot ulcer at baseline.
Study variables Information recorded at diagnosis of diabetes,
such as date of birth, sex and date of diagnosis, were used in the
study. HbA1c measurement taken closest to baseline date, drug
treatment for diabetes (insulin/tablets and glucagon-like pep-
tide-1 [GLP-1] agonists) and eGFRmeasurement taken closest
to baseline date were also included in the study. We did not
have reliable data on smoking, diet or physical activity and the
vast majority of participants (>95%) were from European de-
scent, making it difficult to examine the impact of ethnic var-
iation. Record linkage allowed identification of people with
diabetes who had a history of cardiovascular diseases, using
the International Classification of Diseases, 10th Edition (ICD-
10) codes (http://apps.who.int/classifications/icd10/browse/
2016/en) from hospital records. People with diabetes who
had at least one amputation (either minor or major) or who
died during the 2 years of follow-up were also identified.
Statistical methods Characteristics of people with diabetes
and who had a high-risk of foot ulceration were described.
The primary outcome for people with diabetes who had a
high-risk of foot ulceration was amputation or death.
Kaplan–Meier survival curves were plotted showing survival
probabilities over the whole follow-up period in the three
groups of people with diabetes. Cox proportional hazards
model was used to compare hazards between the three expo-
sure groups, adjusting for all the covariates. The assumption
of proportional hazards was assessed by plotting log negative
log plots for the baseline covariates and fitting time interac-
tions. The assumption of proportional hazards for the expo-
sure variable was violated (see electronic supplementary ma-
terial [ESM] Table 1, ESM Figs 1 and 2). Therefore, the sur-
vival analysis was conducted using parametric regression
models (accelerated failure time) to compare amputation-free
survival up to 2 years between the three exposure groups. The
endpoint included any major amputation (e.g. above ankle
amputation) or minor amputation (e.g. below the ankle). The
starting point was taken as the date of first record of high-risk
of ulceration feet within the study period. The endpoint for
each person with diabetes was whichever one of the following
events came first: end of follow-up (2 years from baseline),
death or amputation.
Accelerated failure time (AFT) models were used to exam-
ine demographic and clinical factors associated with 2 year
survival without amputation for the three groups using χ2. A p
value <0.05 was considered significant. AFT models with
different distributions were fitted, including the generalised
γ, log-logistic, log-normal, Weibull and exponential distribu-
tions. The Akaike’s information criterion (AIC) was used to
select the optimal model (ESM Table 2). The unadjusted and
adjusted estimates of coefficients and 95% CIs are reported.
The models were adjusted for age, sex, duration of diabetes,
HbA1c, eGFR, history of cardiovascular diseases and treat-
ment for diabetes. A secondary analysis was done using am-
putation alone as event. Cox proportional hazards model was
used to model the data as the assumption of proportional haz-
ards was not violated. All analyses were conducted in SAS
version 9.3 (SAS Institute, Cary, NC, USA) using PROC
LIFEREG for AFT models and PROC LIFETEST to plot
the Kaplan–Meier estimates.
Results
Baseline characteristicsBaseline characteristics of participants
with high-risk foot (and no ulcer, active ulcer or healed ulcer)
are shown in Table 1.
There were a total of 17,459 people with diabetes across
Scotland who were identified with high-risk of feet ulceration
from January 2008 to December 2011. Of these people, 106
had a record of both an active foot ulcer at baseline and healed
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ulcer prior to baseline. These people were excluded from the
study as they did not fit into a single baseline study group. A
total of 17,353 people with diabetes and high-risk foot were
included in the study and, of these people, 13,206 (76.1%) had
neither ulcers nor history of previous ulceration at baseline,
1731 (10.0%) people had active ulcers at baseline and 2416
(13.9%) people had healed previous ulcers at baseline. These
people were followed-up for up to 2 years from baseline. The
mean duration of follow-up was 22 months (SD 5.1).
Overall, 56.1%of the 17,353 people in the study samplewere
male and the mean age was 70.1 years (SD 12.2). There were
significant differences between the three groups at baseline in
terms of age, HbA1c, duration of diabetes, type of diabetes treat-
ment, proportion with history of cardiovascular disease, sex dis-
tribution and eGFR. At baseline, people with active foot ulcers
were significantly younger (p < 0.001), had higher HbA1c
(p < 0.001) and a greater proportion weremen (p = 0.001), when
compared with people with previously healed ulcers.
A total of 2694 (15.5%) people with diabetes had an am-
putation or died during the 2 year follow-up period. Of these,
270 (10.0%) had an amputation and 2424 (90.0%) died during
the follow-up period. Although the percentage of events was
highest in people with healed ulcer, the percentage of people
who had an amputation was highest in the active ulcer group.
Overall, the percentage of people who died was 14.0% in all
high-risk individuals, 22.8% in those with previously healed
ulcers, 16% in those with an active ulcer and 12.1% in those
with no previous ulcer. The corresponding percentages of peo-
ple who had an amputation were 1.6%, 1.0%, 2.4% and 1.5%.
AFT model for those identified as having high-risk foot The
crude 2 year amputation-free survival rate in all people with
diabetes who had high-risk foot was 84.5%. Amputation-free
survival was 85.0% in those with no previous or current ulcer,
81.6% in the active ulcer group and 76.1% in the healed ulcer
group. The log-logistic regression model had the lowest AIC.
The unadjusted and adjusted variable estimates for the final
AFT model with log-logistic distribution are reported in
Tables 2 and 3. We found that there was a shorter amputation-
free survival time (i.e. worse outcome) for people who had
active ulcers (p < 0.0001) or healed ulcers (p < 0.0001) at base-
line compared with those who never had an ulcer, after
adjusting for all variables. We also found that people with dia-
betes who were older, were male sex, had longer duration of
diabetes, were treated with tablets or insulin, had higher HbA1c
level, had a history of cardiovascular disease and an eGFR
lower than 30 ml min−1 [1.73 m]−2 had a significantly shorter
amputation-free survival time. Figure 1 shows Kaplan–Meier
curves for the outcome stratified by these exposure groups.
Survival analysis: amputation as an independent event The
main adverse outcome in this study was death. We thus exam-
ined amputation as an independent outcome for people with
diabetes who had high-risk of foot ulceration. People with
diabetes who had an active ulcer at baseline had significantly
higher risk of amputation compared with those who did not
have an ulcer (HR 1.64 [95% CI 1.17, 2.28], p = 0.004) and
with those who had healed ulcer at baseline (HR 2.24 [95%CI
1.37, 3.68], p = 0.001). There was no significant difference in
Table 1 Baseline characteristics of people with high-risk foot screening assessment and main outcomes
Covariate All No ulcer Active ulcer Healed ulcer p valuea
Participants, n 17,353 13,206 1731 2416
Age, years 70.1 (12.2) 70.36 (12.1) 67.74 (12.5) 70.14 (12.2) <0.001
HbA1c, mmol/mol 61.1 (19.5) 60.28 (19.2) 66.5 (20.9) 62.0 (19.4) <0.001
HbA1c, % 7.7 7.6 8.2 7.8
Duration of diabetes, months 115 (58–192) 103 (50–178) 156 (92–237) 152 (92–234) <0.001
Treatment, %
Lifestyle 41.9 42.7 39.7 38.9 <0.001
Tablet/GLP-1 agonist 29.8 31.6 21.7 26.3
Insulin 28.3 25.7 38.6 34.8
History of CVD, % 39.7 40.5 36.2 37.6 <0.001
Sex, % male 56.1 55.8 60.0 54.7 0.001
eGFR, %
<30 ml min−1 [1.73 m]−2 5.2 4.7 7.3 6.6 <0.001
30–60 ml min−1 [1.73 m]−2 59.2 60.4 51.0 58.4
>60 ml min−1 [1.73 m]−2 35.6 34.8 41.7 35.0
Data are shown as mean (SD) or median (interquartile range), unless stated otherwise
a ANOVA for age, Kruskal–Wallis for duration of diabetes, χ2 test for the other categorical variables. Differences between the three groups (no ulcer,
active ulcer and healed ulcer) were classified as significant if p < 0.05
CVD, cardiovascular disease
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risk between people who had a healed ulcer at baseline and
people who did not have an ulcer (p = 0.138).
Discussion
The aim of this study was to compare amputation-free survival
rate in all people with diabetes at high risk of foot ulceration
and not just all people with diabetes or just those with current
ulcers or previous amputation. We also aimed to compare
outcomes for different categories of high risk. The crude 2 year
amputation-free survival rate in all people with high-risk foot
was 84.5% and was 81.6% in the active ulcer group and
76.1% in the healed ulcer group. Thus, people with diabetes
and previously healed ulcers had a worse outcome than people
with an active ulcer, who in turn had a worse outcome than
people with diabetes and no previous foot ulcer. One in four
people with a previously healed ulcer died within 2 years,
while the corresponding figure for people with no previous
ulcer but with high-risk foot was one in eight.
Co-existing renal failure and cardiovascular disease were
the main drivers for this poor outcome. When amputation was
looked at as an independent endpoint, people with active ul-
cers were more than twice as likely to undergo amputation
than those with previous ulcers. This may be because some
clinicians readily choose digit amputation for toe ulcers with
osteomyelitis. Interestingly, the risk of amputation for people
with diabetes who had previous foot ulcers which had healed
was the same as for people with high-risk foot who had never
had an ulcer. However, this may be because individuals in the
former group die before undergoing any amputation and may
point to the importance of managing cardiovascular risk fac-
tors more aggressively for people with diabetes prior to and
subsequent to developing foot ulcer [29]. Earlier studies have
shown that previous ulcers are more likely to predict subse-
quent ulceration compared with other individual risk factors
such as neuropathy or peripheral vascular disease [17–20, 22].
Table 2 Unadjusted and adjusted
estimates for amputation-free sur-
vival in people identified as hav-
ing high-risk of foot ulceration




Active ulcer 1731 319 (18.4) 0.74 (0.66, 0.82)* 0.71 (0.63, 0.79)*
Healed ulcer 2416 577 (23.9) 0.55 (0.51, 0.60)* 0.57 (0.52–0.62)*
No ulcer 13,206 1798 (13.6) – –
a Adjusted for age, sex, duration of diabetes, treatment, HbA1c, history of cardiovascular disease, GFR
measurement
*p < 0.05 vs no ulcer by χ2 test
Table 3 Unadjusted and adjusted
estimates of the association be-
tween the covariates and amputa-
tion-free survival in people iden-
tified as having high-risk of foot
ulceration
Variable Unadjusted time ratio (95% CI) Adjusted time ratio (95% CI)
Age at baseline 0.96 (0.96, 0.97)* 0.96 (0.96, 0.96)*
Sex
Female Ref. Ref.
Male 1.06 (0.99, 1.13) 1.17 (1.09, 1.25)*
Duration of diabetes 1.00 (1.00, 1.00)* 1.00 (1.00, 1.00)*
Treatment
Lifestyle Ref. Ref.
Insulin 0.82 (0.75, 0.89)* 0.79 (0.72, 0.86)*
Tablets/GLP-1 agonist 0.96 (0.96, 1.04) 0.89 (0.82, 0.97)*
HbA1c 1.00 (0.99, 1.02) 1.00 (0.99, 1.00)*
CVD
No history of CVD Ref. Ref.
History of CVD 0.61 (0.57, 0.65)* 0.70 (0.65, 0.75)*
eGFR
>60 ml min−1 [1.73 m]−2 Ref. Ref.
30–60 ml min−1 [1.73 m]−2 0.81 (0.75, 0.87)* 0.95 (0.88, 1.02)
<30 ml min−1 [1.73 m]−2 0.42 (0.37, 0.48)* 0.56 (0.49, 0.63)*
*p < 0.05 by χ2 test
CVD, cardiovascular disease; Ref., reference
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However, we have previously demonstrated that individual
risk factors, even previous ulceration, are not as sensitive as
a global risk score in predicting future foot ulcers [23].
A number of independent risk factors were identified as
being associated with increased risk of death and amputation,
all of which were unsurprising and included increased age,
male sex, increased duration of diabetes, treatment with insu-
lin, poor glycaemic control and history of cardiovascular and
renal disease. Unfortunately, we did not have reliable data on
smoking, diet or physical activity. Although healing rates for
people with active ulcers have been reported to be 65–75%
[18, 25–28], few studies have reported amputation-free sur-
vival. In 2014, Won et al [16] reported that the 1 year
amputation-free survival rate in people with diabetes foot ul-
cers was 65.9% and that severity of ulcer and peripheral artery
disease were risk factors for amputation. Winkley et al report-
ed a similar rate of 69% at 18 months for individuals with
ulcers [9], with older age, ischaemia, ulcer severity and poor
glycaemic control all predicting adverse outcomes. Our
amputation-free survival rate for individuals with high-risk
foot, the majority of whom had no history of an ulcer, was
higher at 84.5%, and our study was a population-based study
including people whose ulcers were managed in the commu-
nity as well as in hospital. To the best of our knowledge, our
study is the first to investigate amputation-free survival rate
and the risk associated in all people with diabetes who had
high-risk foot (as opposed to just those with active ulceration)
and is the first to compare different subcategories of high risk.
The risks of diabetes-related amputation have previously
been shown to be associated with male sex, ethnic group and
deprivation [30], resulting in 5 year mortality rates as high as
34% [31]. We have previously compared diabetes-related am-
putation with non-diabetes-related amputation [32]: the medi-
an times to death were 27 and 47 months, respectively, and
cardiac failure explained the main difference in outcomes.
Looking at these outcomes together with the results of the
current study, it is likely that the poor outcomes in individuals
with high-risk foot are related to social deprivation, sex, eth-
nicity, renal failure and cardiovascular disease (especially car-
diac failure).
Aweakness of this study is that it was an observational study
using routinely collected clinical data and therefore causality
cannot be attributed to any associations found. It is possible that
some endpoints may have been missed but it is not anticipated
that this would be greater in any particular individual subgroup.
Data on smoking, a key risk factor for cardiovascular death and
amputation, were not available. Furthermore, amputation rates
were based on total amputations rather than major and minor
amputations separately. We excluded people with prior amputa-
tions in order to look at incident events. This might explain why
our ulceration rate, at 0.7%, was lower than the expected rate of
around 1.7% [22]. If individuals with prior amputations had been
included, it is likely that the majority of these people would have
been categorised in the ‘previous ulcer’ group. Many might also
have been in the ‘active ulcer’ group, since ulcers pre-date most
amputations in the diabetic foot [1]. Hence, it is likely that the
differences in outcomes between each of the three exposure
groups would have been exaggerated if individuals with prior
amputation were included. The data do, however, represent nor-
mal routine practice and was collected across Scotland from all
14 Health Boards, each of which will have had some variation in
clinical practice. The results are thus likely to be relevant to
clinical practice in developed countries.
The current study demonstrates that in people with diabetes
who have high-risk foot, the risk of premature death was up to
nine times the risk of amputation. Individuals with previous
foot ulcers were at greater risk of death during follow-up than
those with active ulcers. Those with diabetes with active ul-
cers had a higher risk of amputation than those with previous-
ly healed ulcers.
Fig. 1 Kaplan–Meier survival
curve showing amputation-free
survival in people identified as
having high-risk of foot
ulceration. The healed ulcer group
had the lowest amputation-free
survival rate compared with the
group with no previous or current
ulcer and the active ulcer group.
Red line, no ulcer; green line,
active ulcer; blue line, healed
ulcer
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